Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Ironwood Buys AstraZeneca's Zurampic As Ideal Linzess Complement

Apr 26 2016

• By Joseph Haas

Related Content

AstraZeneca looks to combos after effective ex-Ardea drug shows serious adverse effects

Dec 15 2013

AZ's lesinurad misses in Phase III gout at lower dose

Jun 16 2015

AZ's Gout Drug Gets FDA Go-Ahead With Safety Caveats

Dec 23 2015

FDA: AZ/Ardea Gout Drug Modest Efficacy, Safety Concerns

Oct 22 2015

AstraZeneca to pay $1.26 billion for Ardea and its gout product

Apr 23 2012

Related Companies

Ironwood Pharmaceuticals, Inc.

AstraZeneca PLC

Additional Topics

United States Deals Inflammation

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window